ResearchMoz added Latest Research Report titled " Global Breast Cancer Market: Industry Analysis & Outlook (2017-2021) " to it's Large Report database.
Breast cancer defines a malignant tumor that has developed from cells in the breast. Some breast cancers are called in situ as they are confined within the ducts (ductal carcinoma in situ or DCIS) or lobules (lobular carcinoma in situ or LCIS) where they originated. Although, less commonly, breast cancer can also instigate in the stromal tissues, which include the fatty and fibrous connective tissues of the breast. In the early stages, breast cancer may not cause any symptoms. A lump may be too small to feel or to cause any unusual changes that could be noticed on own. Typically, an abnormal area shows up on a screening mammogram which leads to further testing. Several risk factors including smoking and alcohol consumption, exposure to estrogen, gender, age, radiation therapy, family history and personal history are linked to the growth of breast cancer.
The global market for breast cancer has grown swiftly over the past few years driven by introduction of several new drugs and biosimilars. The overall breast cancer market remained mainly dominated by the generic drugs. The future market for breast cancer will grow in the coming years as there exist unmet need for new drugs that would overcome resistance and prevent recurrence of the disease.
Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=964493
The global breast cancer market is likely to grow strongly in the coming years driven by rising healthcare expenditure, rising diabetic and obese population, increased spending on medicines, increasing consumption of alcohol and tobacco and rising female population above 65 years of age. Key trends of the market includes rising development of PARP inhibitors, clinical trials of CDK4/6 inhibitors and introduction of new imaging tests. However, growth of the market can be hindered by several factors including drug development challenges in developing countries, long term side effects of drugs and heavy costs associated with drug development.
The report “Global Breast Cancer Market: Industry Analysis & Outlook (2017-2021)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the U.S., Europe and APAC regions along with the global market. The report profiles the key players of the market including Johnson & Johnson, AbbVie, AstraZeneca and Roche.
Browse more details @ http://www.researchmoz.us/global-breast-cancer-market-industry-analysis-outlook-20172021-report.html
Table of Content
1. Introduction
1.1 Market Overview
2. Global Breast Cancer Market
2.1 Global Breast Cancer Market by Value
2.2 Global Breast Cancer Market Forecast by Value
2.3 Global Breast Cancer Market by Region
2.4 Global Breast Cancer Drug Development by Stages
3. Regional Breast Cancer Market
3.1 The U.S.
3.1.1 The U.S. Breast Cancer Market by Value
3.1.2 The U.S. Breast Cancer Market Forecast by Value
3.1.3 The U.S. Breast Cancer Market by Addressable Population
3.1.4 The U.S. Breast Cancer Market Forecast by Addressable Population
3.1.5 The U.S. Breast Cancer Population by Age
3.2 Europe
3.2.1 EU5 Breast Cancer Market by Value
3.2.2 EU5 Breast Cancer Market Forecast by Value
3.3 APAC
3.3.1 APAC Breast Cancer Market by Value
3.3.2 APAC Breast Cancer Market Forecast by Value
3.3.3 APAC Breast Cancer Market by Countries
3.3.4 Japan’s Breast Cancer Market by Value
3.3.5 Japan’s Breast Cancer Market Forecast by Value
3.3.6 China’s Breast Cancer Market by Value
3.3.7 China’s Breast Cancer Market Forecast by Value
3.3.8 Australia’s Breast Cancer Market by Value
3.3.9 Australia’s Breast Cancer Market Forecast by Value
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/
ResearchMoz added Latest Research Report titled " Global Cancer Diagnostic Market with Focus on Lung and Breast Cancer (2016-2020) " to it's Large Report database.
Scope of the Report
The report entitled Global Cancer Diagnostic Market with Focus on Lung and Breast Cancer (2016-2020), provides analysis of the global cancer diagnostics market and the US cancer diagnostics market, with detailed analysis of market size and growth, penetration and market share. The report also provides the analysis of the global and the US cancer market, by prevalence, new cases, deaths, type of cancers, etc. The report provides the market sizing of the global lung and breast cancer diagnostic market by value and by segments.
The report also discusses about the different diagnostic test of lung cancer and breast cancer. The diagnostics test analyzed in the report are: MetaStat (Meta Test) (Breast Cancer Test), OncotypeDX (Breast Cancer Test), OncoCyte (Lung Cancer Test), Veracytes Test (Lung Cancer Test) and Integrated Diagnostics, Inc. Test (Lung Cancer Test).
Country Coverage
North America (US)
Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=841071
Executive Summary
A disease caused by abnormal growth of cells in the body, is called Cancer. In this disease, the formation of new cells slows or start dividing, forming lumps. However, all lumps are not cancerous; and this can be known by diagnosis.
There are various types of cancer- prostate cancer, breast cancer, lung and bronchus cancer, colon and rectum cancer, bladder cancer, melanoma of the skin, non-hodgkin lymphoma, kidney and renal, pelvis cancer, thyroid cancer, endometrial cancer and others.
Cancer is diagnosed using various tools, which confirm the presence of tumour, and the rate of its growth within the body. Cancer diagnosis can be segmented into: imaging testing, endoscopy, biopsy and tumour marker. Each segment can be sub segmented.
The global cancer diagnostic market is expected to increase at a significant growth rate during the forecasted period (2016-2020). The global cancer diagnostic market is supported by various growth drivers, such as the rising incidence of cancer, sedentary lifestyle, growing technological advancement, increasing awareness, etc.
Browse more details @ http://www.researchmoz.us/global-cancer-diagnostic-market-with-focus-on-lung-and-breast-cancer-2016-2020-report.html
Table of Content
1. Executive Summary
2. Introduction
2.1 Cancer Overview
2.2 Cancer Diagnostic: Overview
2.3 Cancer Diagnostic: Liquid Biopsy
3. Market Analysis
3.1 Cancer Prevalence Analysis
3.1.1 Global Cancer New Cases and Death
3.1.2 Global Cancer Prevalence, New Cases and Death by Type
3.1.3 US Cancer Prevalence
3.1.4 US Cancer New Cases and Death by Type
3.2 Cancer Diagnostic Market Analysis
3.2.1 Global Cancer Diagnostic Market by Value
3.2.2 Global Cancer Diagnostic Market by Segments (Type of Tests)
3.2.3 Global Cancer Diagnostic Market by Segments (Type of Cancer)
3.2.4 Global Cancer Diagnostic Market by Region
3.2.5 North America Cancer Diagnostic Market by Value
3.3 Lung Cancer Diagnostic Market Analysis
3.3.1 Global Lung Cancer Diagnostic Market by Value
3.3.2 Global Lung Cancer Diagnostic Market by Segment (Type of Test)
3.3.3 Global Lung Cancer Cases by Type
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/
ResearchMoz added Latest Research Report titled " Cancer Immunotherapy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024 " to it's Large Report database.
Global Cancer Immunotherapy Market: Overview
The growing incidences of cancer and a need to treat them is the key driver of the global immunotherapy market. The number of deaths occurring due to cancer is increasing every year and has therefore forced government bodies to take initiatives for the improvement of the health conditions of people, by investing heavily in research and development and enabling innovation and advancements in technology so as to offer improved treatments. This has pushed the growth of the global cancer immunotherapy therapy. As immunotherapy therapy has a higher success rate and proven efficiency over conventional treatment methods for cancer, its demand is higher and therefore, the market is expected to witness a remarkable growth over the coming years. The treatment pipeline looks promising and is thus, expected to ensure a healthy growth of the market.
The report offers forecasts of the overall cancer immunotherapy market over the global level as well as on regional levels. The estimated size of each of the segments and sub-segments has also been given in the report. Macroeconomic indicators, drivers, and restraints impacting the global cancer immunotherapy market have been included along with their impact on each region.
Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=910648
Current challenges met by players in the cancer immunotherapy market have been elaborated on, thus giving a brief idea to readers and investors the problems they may encounter while investing in the competitive market.
Global Cancer Immunotherapy Market: Trends and Drivers
The global cancer immunotherapy market is expected to hold promising growth as there lies immense scope for improvement and development. The increasing number of clinical trials held particularly in immunotherapy is expected to boost the market’s growth. With the recognition from various medical bodies as the foremost line of therapy over conventional chemotherapy, cancer immunotherapy is estimated to hold immense potential and growth opportunity in the coming years.
However, factors such as high attrition rates during product development phase are anticipated to restrict the growth of the market. Also, an overall lack of awareness about immunotherapy being a better treatment option will impede the growth of the market. The high cost of clinical trials poses a challenge for players in the market.
Browse more details @ http://www.researchmoz.us/cancer-immunotherapy-market-global-industry-analysis-size-share-growth-trends-and-forecast-2016-2024-report.html
Table of Content
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Cancer Immunotherapy Market
4. Market Overview
4.1. Introduction
4.1.1. Market Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Key Market Indicators
4.3.1. Region/Country Specific
4.3.2. Product/Therapeutic Area Specific
4.3.3. Target Market Specific – Global Scenario
4.4. Market Dynamics
4.4.1. Drivers
4.4.2. Restraints
4.4.3. Opportunity
4.4.4. Trends
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/
ResearchMoz added Latest Research Report titled " Global Cancer Immunotherapies Market 2016-2020 " to it's Large Report database.
About Cancer Immunotherapies
Cancer immunotherapy works by enhancing the innate powers of the immune system. This has better chances of successfully fighting cancer for a long period. Also, immunotherapies have fewer side effects and can treat different types of cancer. Cancer immunotherapies make up nearly 50% of the cancer drugs market.
Technavios analysts forecast the global cancer immunotherapies market to grow at a CAGR of 15.17% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global cancer immunotherapies market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of cancer immunotherapies used to treat cancer.
Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=715922
The market is divided into the following segments based on geography:
Americas
APAC
EMEA
Technavio's report, Global Cancer Immunotherapies Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
Amgen
Bristol-Myers Squibb
F. Hoffmann-La Roche
GlaxoSmithKline
Merck
Browse more details @ http://www.researchmoz.us/global-cancer-immunotherapies-market-2016-2020-report.html
Table of Content
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Overview of cancer immunotherapies
Epidemiology
Spending on cancer
Cost of cancer treatment
Reimbursement policies
Economic burden of cancer
Orphan drug designation and regulatory approvals
PART 06: Pipeline portfolio
Anticipated number of products with single and multi-indications by 2020
PART 07: Market landscape
Market overview
Market size and forecast
Five forces analysis
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/
ResearchMoz added Latest Research Report titled " Colorectal Cancer - Heat Map and Analysis " to it's Large Report database.
Colorectal cancer (CRC), otherwise known as bowel cancer, is a malignancy originating in the colon (the large intestine) or rectum, both of which are located towards the end of the human gastrointestinal tract. It begins as a benign tumor, which is almost always in the form of a small polyp within the colon or rectum. It rarely occurs in the absence of polyps, although can arise as a result of an inflammatory bowel disease such as Crohn’s disease or ulcerative colitis. CRC was the third most prolific oncological indication with regard to the number of new cases in the US in 2016.
The disease can be divided into two categories based on how advanced it is upon diagnosis. These are early-stage (adjuvant) CRC, which can be treated with surgery, and metastatic (advanced) CRC, which cannot. Therapeutic options differ between the two treatment settings, with therapies for adjuvant CRC aiming to prevent disease re-occurrence and those for advanced conditions aiming to slow disease progression while maintaining the patient’s quality of life.
Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=984797
Targeted therapies have already begun to extend the lifespan of metastatic CRC patients compared with chemotherapy-only regimens. However, there remains an unmet need to improve the efficacy of treatment options and extend survival for these patients. Additionally, an unmet need exists for patients with KRAS mutation-positive CRC, for whom certain currently marketed therapies are not recommended.
This tabular heatmap framework, designed to provide an easily digestible summary of these clinical characteristics, provides detailed information on all late-stage clinical trial results for products in the CRC market, with additional focus on the late-stage pipeline. These are split along therapy lines, and are therefore reflective of the treatment algorithm.
All safety and efficacy endpoints reported in these trials are displayed, for both the drug and placebo groups. In addition, key study characteristics such as the size, composition and patient segment of the study population are provided. These results are presented in a visually accessible, color-coded manner in order to maximize ease of use.
Read All Cancer Market Research Reports @ http://www.researchmoz.us/cancer-market-reports.html
Table of Contents
1 Table of Contents
1 Table of Contents 2
2 Introduction 3
2.1 Report Guidance 6
3 Marketed Products 7
3.1 Early-Stage Adjuvant Therapy 7
3.2 Advanced (Unresectable or Metastatic) Therapy 8
3.2.1 Chemotherapy 9
3.2.2 Targeted Therapies 10
4 Pipeline Products 13
4.1 Changes to Early-Stage Adjuvant Therapies, 2017–2022 13
4.2 Changes to Advanced (Unresectable or Metastatic) Therapies, 2017–2022 13
4.2.1 Changes to Chemotherapies, 2017–2022 13
4.2.2 Changes to Targeted Therapies, 2017–2022 14
5 Appendix 17
5.1 Abbreviations 17
5.2 References 18
5.3 Research Methodology 21
5.4 Contact Us 21
5.5 Disclaimer 21
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/
ResearchMoz added Latest Research Report titled " Prostate Cancer Market to 2021 - Increasing Disease Prevalence to be a Key Driver of Market Growth " to it's Large Report database.
Prostate Cancer (PC) is a disease predominately of the elderly with 60% of cases diagnosed in men aged 65 or over. Prostate cancer is slow growing, and asymptomatic at its earliest stages. However, with the use of digital rectal examination, the PSA test, and the incidental discovery of tumors following resection of the prostate, the majority of PC cases are diagnosed at an early stage (60%). As PC is slow growing, many patients can leave their disease untreated for extended periods of time with frequent monitoring (watchful waiting or active surveillance), with many patients dying from other causes before treatment is indicated. Surgery and/or radiotherapy is often curative when treatment is indicated for localized disease, with androgen deprivation being the standard of first-line care. However, most patients ultimately develop resistant disease, for whom treatment options have historically been limited, with treatment with docetaxel being standard. The recent approval of Zytiga and Xtandi for docetaxel refractory disease in 2011 and 2012 have improved survival of resistant patients, but there is a clear clinical need to diversify the treatment options for this patient cohort.
Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=494550
The current late-stage drugs in development for PC address this clinical need, however, results so far have been mixed, with none demonstrating clinically transformative efficacy of safety. As a result, the growth in PC prevalence as a result of a global aging population is expected to be the key driver of this market throughout the forecast period.
Scope
- Global revenues for the PC market are forecast to rise at a moderate CAGR of 9.5% from $7.6bn in 2014 to $13.6bn in 2021.
- What factors are driving the market growth?
- How can the factors limiting growth be overcome in the future?
- The pipeline addresses clinical need in the market; seven of the nine late-stage pipeline products are being developed as therapies for metastatic castration resistant disease.
- What other gaps in the market are being addressed by the current pipeline dynamics?
- The variation in molecule type has shifted away from small molecules (predominately hormonal therapies), the dominance of which has decreased from 91% across marketed products to 50% across the pipeline.
Read All Cancer Market Research Reports @ http://www.researchmoz.us/cancer-market-reports.html
Table of Contents
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 10
2.1 Disease Introduction 10
2.2 Symptoms and Risk Factors 10
2.3 Etiology and Pathophysiology 11
2.4 Diagnosis 13
2.4.1 Digital Rectal Examination 13
2.4.2 Imaging 13
2.4.3 Biopsy 13
2.4.4 Tumor Markers 14
2.5 Disease Staging and Risk Assessment 15
2.6 Treatment Algorithm 17
2.6.1 Localized or Locally Advanced Prostate Cancer 17
2.6.2 Hormone Sensitive Metastatic Prostate Cancer 19
2.6.3 Metastatic Castration Resistant Prostate Cancer 23
2.6.4 Heat Map – Marketed Products Overview 27
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/
ResearchMoz added Latest Research Report titled " Global Urological Cancer Market to 2022 - Strong Growth Driven by Rising Prevalence, Increased Uptake of Hormone Therapies and Approval of Novel Biologics " to it's Large Report database.
Urological Cancers are thought to account for 19.5% of global cancer prevalence, with kidney, prostate, testicular and bladder cancer - the key indications covered in this report - accounting for the majority of that figure. Urological cancers affect the male and female urinary tract and the male reproductive organs. Prostate cancer is the most prevalent of these malignancies.
A number of common etiologic factors have been strongly characterized as raising the risk of developing urological cancers, including age, chronic inflammation, gender, obesity, tobacco usage and heritable cancer syndromes. The risk of cancer increases greatly in patients over the age of 65. Populations in developed countries are projected to become increasingly aged and show rising obesity incidence, which will drive both cancer prevalence and revenue growth for its treatments.
Hormone therapies for prostate cancers and angiogenesis inhibitors for renal cell carcinoma are currently the most commercially successful urological cancer drugs. However, there has been a shift towards the clinical testing of cancer immunotherapies – such as Opdivo, which was recently approved for renal cell carcinoma.
Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=759626
The forecast period will also witness the approval of a greater number of targeted therapies, which by their nature have less toxicity associated with their use, and as a result can be administered to patients with poor performance statuses, therefore increasing the overall survival of this group and the number of treatment cycles they may receive.
Scope
- Global revenues for the urological cancer market are forecast to grow at a Compound Annual Growth Rate (CAGR) of 10.39%, from $17.9 billion in 2015 to $35.9 billion in 2022. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?
- The urologic oncology pipeline is large and diverse, and contains 817 products. How does the composition of the pipeline compare with that of the existing market?
- What mechanisms of action and molecule types are most common for pipeline drugs being trialed in the various key indications?
- How will the market shares and CAGRs of the top 20 companies compare within this therapy area?
- What proportion of the key players’ revenues will be attributable to urological cancers?
Read All Cancer Market Research Reports @ http://www.researchmoz.us/cancer-market-reports.html
Table of Contents
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6
2 Introduction 9
2.1 Disease Cluster Introduction 9
2.2 Symptoms 9
2.3 Etiology and Pathophysiology 10
2.3.1 Etiology 10
2.3.2 Pathophysiology 11
2.4 Co-morbidities and Complications 13
2.5 Epidemiology Patterns; Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates 13
2.5.1 Bladder Cancer 14
2.5.2 Kidney Cancer 15
2.5.3 Prostate Cancer 15
2.5.4 Testicular Cancer 16
2.6 Treatment 17
2.6.1 Chemotherapy 17
2.6.2 Surgery and Radiation Therapy 19
2.6.3 Hormonal Therapies 21
2.6.4 Targeted Therapies 22
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/
ResearchMoz added Latest Research Report titled " Gallbladder Cancer - Pipeline Review, H2 2016 " to it's Large Report database.
Gallbladder Cancer - Pipeline Review, H2 2016
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gallbladder Cancer Pipeline Review, H2 2016, provides an overview of the Gallbladder Cancer (Oncology) pipeline landscape.
Gallbladder cancer is a cancer that starts in the gallbladder. Symptoms include abdominal pain, nausea and/or vomiting, jaundice, loss of appetite, fever, itchy skin, dark urine and weight loss. Risk factors include overweight, age, family history, gallstones, gender and choledochal cysts. Treatment includes surgery, chemotherapy and radiation therapy.
Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=889483
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gallbladder Cancer Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Gallbladder Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Gallbladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gallbladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Phase I stages are 7 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.Gallbladder Cancer.
Read All Cancer Market Research Reports @ http://www.researchmoz.us/cancer-market-reports.html
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Gallbladder Cancer Overview 6
Therapeutics Development 7
Pipeline Products for Gallbladder Cancer - Overview 7
Pipeline Products for Gallbladder Cancer - Comparative Analysis 8
Gallbladder Cancer - Therapeutics under Development by Companies 9
Gallbladder Cancer - Therapeutics under Investigation by Universities/Institutes 10
Gallbladder Cancer - Pipeline Products Glance 11
Clinical Stage Products 11
Gallbladder Cancer - Products under Development by Companies 12
Gallbladder Cancer - Products under Investigation by Universities/Institutes 13
Gallbladder Cancer - Companies Involved in Therapeutics Development 14
4SC AG 14
harma Inc 14
BeiGene Ltd 16
Eli Lilly and Company 17
Novartis AG 18
VasGene Therapeutics Inc 19
Gallbladder Cancer - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/
